Volume 4.21 | May 31

Mammary Cell News 4.21 May 31, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Skp2 Activates Cancer-Promoting, Glucose-Processing Akt
Scientists report that HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism. They also found that this chain of events promotes Herceptin resistance in breast cancer and activation of glucose metabolism. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Cell]
Press Release | Abstract

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
This study provided evidence for the key role of CCL5/CCR5 in the invasiveness of basal breast cancer cells and suggested that CCR5 antagonists may be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype. [Cancer Res] Abstract

Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes
Researchers suggest that during breast cancer liver metastasis, claudin-2 shifts from acting within tight-junctional complexes to functioning as an adhesion molecule between breast cancer cells and hepatocytes. [Mol Cell Biol] Abstract

Loss of Plakoglobin Promotes Decreased Cell-Cell Contact, Increased Invasion and Breast Cancer Cell Dissemination In Vivo
Researchers demonstrated a functional role for plakoglobin in the shedding of tumor cells from the primary site into the circulation. [Breast Cancer Res] Abstract | Full Article

The Forkhead Box Transcription Factor FOXC1 Promotes Breast Cancer Invasion by Inducing Matrix Metalloprotease 7 (MMP7) Expression
Scientists demonstrated for the first time a correlation between MMP7 expression and basal-like breast cancers, suggesting that MMP7 may be a useful therapeutic target for treatment of this disease. [J Biol Chem] Abstract | Full Article

YAP Promotes Breast Cell Proliferation and Survival Partially through Stabilizing the KLF5 Transcription Factor
Investigators demonstrated that Yes-associated protein (YAP) functions partially through its binding to KLF5, a transcription factor that promotes breast cell proliferation and survival. [Am J Pathol] Abstract

Simultaneous Mitochondrial Ca2+ Overload and Proteasomal Inhibition are Responsible for the Induction of Paraptosis in Malignant Breast Cancer Cells
Scientists found that simultaneous inhibition of the mitochondrial Na+/Ca2+ exchanger and proteasomes can trigger a sustained mitochondrial Ca2+ overload and effectively induce paraptosis in malignant breast cancer cells. [Cancer Lett] Abstract

Methylseleninic Acid Restricts Tumor Growth in Nude Mice Model of Metastatic Breast Cancer Probably via Inhibiting Angiopoietin-2
Researchers investigated levels of angiopoietin-2 (Ang-2) and vascular endothelial growth factor on the estrogen-independent bone metastatic mammary cancer cells in response to treatment by methylseleninic acid. [BMC Cancer] Abstract | Full Article

Metformin Elicits Anticancer Effects through the Sequential Modulation of DICER and c-MYC
Researchers found that metformin affects engraftment and growth of breast cancer tumors in mice. They also demonstrated that microRNA modulation underlies the anticancer metabolic actions of metformin. [Nat Commun] Abstract

CLINICAL RESEARCH

Safety Results from a Phase III Study (TURANDOT Trial by CECOG) of First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER-2-Negative Locally Recurrent or Metastatic Breast Cancer
Researchers report safety data from a randomized, phase III study evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer. [Eur J Cancer] Abstract

Chromosome Instability and Benefit from Adjuvant Anthracyclines in Breast Cancer
Investigators used fluorescent in situ hybridization for chromosomes 1, 7, 11, 17 and 18 to identify patients with high percentages of tumor chromosome instability in the 322 patients recruited into the BR9601 clinical trial. [Br J Cancer] Abstract

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study
Scientists identified a sub-group of Tamoxifen-treated breast cancer patients with microRNA-expressing tumors associated with cancer stem cell characteristics. [PLoS One] Full Article

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

INDUSTRY NEWS

Karolinska University Hospital and GE Healthcare Collaborate to Advance Technologies for Cell Therapy
Karolinska University Hospital Sweden and General Electric (GE) Healthcare Life Sciences announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy. [General Electric Company] Press Release

Doug Ulman, National Cancer Survivorship Advocate, Joins Provectus Pharmaceuticals’ Corporate Advisory Board
Provectus Pharmaceuticals, Inc. has appointed Doug Ulman to its Corporate Advisory Board. [Provectus Pharmaceuticals, Inc.] Press Release

POLICY NEWS

White House Petitioned to Make Research Free to Access
More than 17,000 people have signed an online petition urging US President Barack Obama to require all scientific journal articles resulting from US taxpayer-funded research to be made freely available online. [White House, United States] Press Release

Horizon 2020: A €80 Billion Battlefield for Open Access
As negotiations proceed to shape the next installment of Europe’s gargantuan research funding programs, scientists, librarians, and publishers are eagerly awaiting the answer to a critical question: How strong will the new seven-year program, called Horizon 2020, be on Open Access? [European Commission, European Union] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 14th International Biennial Congress of the Metastasis Research Society: Metastasis Research Conference 2012
September 2-5, 2012
Brisbane, Australia

Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoc Positions – Molecular Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)



Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us